NxStage Medical, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 84   

Articles published

NXTM 16.95 +0.29 (1.74%)
price chart
NxStage Medical (NXTM) Q4 Loss Narrower than Expected
Manufacturer of innovative dialysis products, NxStage Medical Inc. (NXTM - Snapshot Report), reported adjusted loss of 8 cents per share in the fourth quarter of 2014, narrower than the Zacks Consensus Estimate of loss by a couple of cents.
NxStage Medical Rating Lowered to Neutral at Zacks (NXTM)  The Legacy
Revenue Update on NxStage Medical, Inc.  Markets Bureau
Insider Transaction Update: NxStage Medical, Inc. President Sells Company ...
NxStage Medical, Inc. (NASDAQ:NXTM), According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the President of NxStage Medical Inc, Turk Joseph E Jr had sold 2,082 shares worth of $37,226 in a transaction ...
Zacks Lowers NxStage Medical to Neutral (NXTM)  sleekmoney
NxStage Medical PT Raised to $27.00 at Canaccord Genuity (NXTM)  The Legacy
NxStage Medical Inc. (NXTM) is Trading Lower on Unusual Volume for February ...
NxStage Medical Inc. ($NXTM) experienced unusually high volume on Feb. 27, as the stock lost 5.14% to a closing price of $17.18.
Why NxStage Medical Inc. Stock Surged Higher
Why it's happening: For the quarter, NxStage Medical reported a 13% increase in revenue to a record $75.3 million, which happened to be higher than the prior guidance issued by the company of $71 million-$72.5 million issued during its second-quarter ...
Why Are Traders Paying Attention To Uranium Energy Corp.(NYSEMKT:UEC ...  Scibility Media
Related articles »  
Analyst Rating Update on NxStage Medical, Inc.
Analysts at Zacks have given a short term rating of buy on Nxstage Medical (NASDAQ:NXTM) with a rank of 2. The counter has received an average rating of 2 from 6 brokerage firms.
NxStage Medical Inc. (NXTM) is Trading Higher on Unusual Volume for February ...
NxStage Medical Inc. ($NXTM) experienced unusually high volume on Feb. 26, as the stock gained 0.17% to a closing price of $18.11.
Latest Updates on the Healthcare Sector: Complementary Research on NxStage ...
NxStage Medical, Inc (NxStage Medical) will release its financial results for the fourth quarter and full year ended December 31, 2014, on Thursday, February 26, 2015, before the financial markets open.
NxStage Medical Receives Consensus Recommendation of �Buy� from Analysts ...
Analysts have set a twelve-month consensus price target of $20.75 for the company and are forecasting that the company will post ($0.09) EPS for the current quarter, according to Zacks. Zacks has also assigned NxStage Medical an industry rank of 100 ...
Why NxStage Medical Inc. Shares Slumped
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
Related articles »  
ReWalk Robotics names NxStage Medical exec as new CFO
Kevin W. Hershberger, former controller and chief accounting officer at NxStage Medical Inc., as CFO starting Jan. 1. Ami Kraft, who had been serving as ReWalk's CFO, to a new role as general manager of ReWalk's Israel organization, and will assume his ...